EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia



The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia



Leukemia (Basingstoke) 11(12): 2039-2044



Sixty-six adults with refractory acute lymphocytic leukemia received salvage therapy with the 'hyper-CVAD' regimen, consisting of eight courses of alternating intensive chemotherapy with growth factor support, followed by oral maintenance chemotherapy. Their outcome was compared with 63 prognostically similar historical control patients treated with high-dose Ara-C plus mitoxantrone with or without GM-CSF. Overall, the complete response rates were similar in the treatment and control groups (29 of 66 (44%) vs 24 of 63 (38%)). There were more patients in the current study with primary resistant disease (10 of 66 (15%) vs one of 63 (2%), P = 0.006), and conversely fewer patients with secondary resistance (19 of 66 (29%) vs 28 of 63 (44%), P = 0.06). Recovery of granulocyte counts above 500/mul was significantly faster in the current study when compared to high-dose Ara-C-treated patients who were given GM-CSF (20 vs 25 days, P = 0.04). Survival was prolonged in the hyperCVAD-treated patients, with most of the benefit seen in first salvage patients (42 vs 20 weeks, P = 0.016). When only first salvage patients were considered, there was a significant difference in disease-free survival in favor of hyper-CVAD (52 vs 20 weeks, P = 0.008). The hyper-CVAD regimen is a more effective and less toxic salvage regimen for relapsed acute lymphocytic leukemia than high-dose Ara-C-based regimens.

Accession: 009584953

Download citation: RISBibTeXText

DOI: 10.1038/sj.leu.2400861



Related references

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11(12): 2039-2044, 1998

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology 28(24): 3880-3889, 2010

Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia 15(1): 52-57, 2015

Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia Research 39(3): 323-328, 2015

Clinical characteristics and treatment outcome of adult acute lymphoblastic leukemia with t(4;11)(q21;q23) using a modified hyper-CVAD regimen. Acta Haematologica 122(1): 23-26, 2009

Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 26(15_suppl): 7019-7019, 2016

Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study. Acta Haematologica 130(3): 199-205, 2013

Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico. Revista Peruana de Medicina Experimental Y Salud Publica 31(3): 525-529, 2014

Treatment of Adult Acute Lymphoblastic Leukemia with the Hyper-CVAD Regimen Preliminary Analysis from a Single Center. Blood 100(11): Abstract No 4617, November 16, 2002

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23): 3650-3656, 2016

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M√ľnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. American Journal of Hematology 91(8): 819-823, 2016

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. Haematologica 102(5): E184-E186, 2017

Single centre experience with the Hyper-CVAD regimen in adult acute lymphoblastic leukemia Preliminary analysis of efficacy and toxicity. Blood 98(11 Part 2): 216b, November 16, 2001

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers. ChemoTherapy 60(4): 219-223, 2015

Update of the modified hyper-CVAD regimen with or without rituximab as frontline therapy of adults with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (ILL). 2007